Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is being done in 2 parts. The first part is to determine the dose of RAD001 that
should be used in combination with sorafenib. The second part is using the above determined
dose of RAD001 in combination with sorafenib to see how effective these 2 drugs are against
advanced kidney cancer.
Participants will be asked to keep a pill diary.